Schlafen 11 Assessment in High-Grade Serous Ovarian Carcinoma Phenotypic and Histological Distribution
ANALYTICAL AND QUANTITATIVE CYTOPATHOLOGY AND HISTOPATHOLOGY
Authors: Ferraioli, Domenico; Penuela, Leonardo; Garuti, Anna; Carrozzi, Chiara; Olivier, Timothee; Spina, Bruno; Salvi, Sandra; Ferrero, Simone; Tille, Jean-Christophe; Labidi-Galy, Sana Intidhar; Cirmena, Gabriella; Ballestero, Alberto; Chopin, Nicolas; Beurrier, Frederic; Treilleux, Isabelle; Ray-Coquard, Isabelle; Zoppoli, Gabriele; Vellone, Valerio Gaetano
Abstract
OBJECTIVE: To develop a protocol for immunohistochemistry (IHC) to determine the Schlafen 11 (SLFN11) expression in formalin-fixed, paraffin-embedded (FFPE) high-grade serous ovarian carcinoma (HGSOC) samples. STUDY DESIGN: We validated a reliable SLFN11 antibody (SLFN11-Ab) in IHC choosing between 2 anti-SLFN11-Abs used for western blot through the development of a SLFN11-IHC protocol in culture cell block (CCB) of ovarian carcinoma and in an HGSOC tissue microarray (TMA) series. We applied our protocol to a case series of HGSOC samples to confirm our preliminary results. For each case we evaluated both the intensity score (IS) and the distribution score (DS). A final histological score (HS) was obtained as follows: HS=IS x DS. RESULTS: In CCB and TMA series, the antibody #1 at at 1:100 dilution was more reliable. This last one was used in our case series to confirm our IHC protocol. DS showed the following results: 27 cases were no stain, 11 cases showed staining for SLFN11 in <10% of cells, 16 cases showed staining in 10-40% of cells, and the remaining 15 cases showed stain in >40% of cells. IS showed the following results: 25 cases were no stain, in 19 cases a dominant weak stain, in 14 cases a moderate stain, and in 11 cases a strong stain. HS for SLFN11 expression presents a normal distribution with a prevalent (approximate to 60%) intermediate expression. CONCLUSION: We develop a reproducible and standardized IHC protocol to determinate the SLFN11 expression in FFPE HGSOC samples using a modified western blot anti-SLFN11-Ab.
SLFN11 expression (exp) in castration-resistant prostate cancer (CRPC) patients (pts) to predict response to platinum-based chemotherapy (PLT).
JOURNAL OF CLINICAL ONCOLOGY
Authors: Conteduca, Vincenza; Puca, Loredana; Ku, Sheng-Yu; Hess, Judy; Kearney, Megan; Fernandez, Luisa; Bareja, Rohan; Vlachostergios, Panagiotis J.; Sigouros, Michael; Mosquera, Juan Miguel; Sboner, Andrea; Nanus, David M.; Elemento, Olivier; Dittamore, Ryan; Tagawa, Scott T.; Beltran, Himisha
Abstract